Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Similars in SciELO
Share
Revista Costarricense de Cardiología
Print version ISSN 1409-4142
Abstract
SALAZAR-SANCHEZ, Lizbeth et al. The importance of the determination of Factor X acivated for anticoagulation with low molecular weight heparins experience at the Hospital San Juan de Dios. (First report) 2009-2011. Rev. costarric. cardiol [online]. 2012, vol.14, n.1-2, pp.09-13. ISSN 1409-4142.
Anticoagulation is an important therapeutic tool for patients with thromboembolic disease who receive therapy with low molecular weight heparins (LMWH). This report gives evidence about the importance of determining the activity of Anti-Xa activity for monitoring enoxaparin and for identifying those patients who need this analysis based on some risk factors. Methods: We studied 34 adult patients who received enoxaparin as anticoagulation therapy during the period 2009- 2011. We performed a descriptive analysis of demographic and clinical characteristics of all patients, indicating the reasons for anticoagulation, comorbidities and type of anticoagulation. We determined the anti-Xa activity 4 hours after administration of enoxaparin. Results: The mean age of patients was 62,3 + 17,7 years, regardless of gender. 72,7% of patients received enoxaparin as therapy for an acute coronary syndrome. The most frequent comorbidity was hypertension. The average of renal clearance was 62,47 ml/min, only three patients had a renal clearance below 30 ml/min. 44,1% of the patients were obese. 55, 9% of patients were within therapeutic levels of anti Xa activity and 35,3% of patients had an anti-Xa activity considered as prophylactic. Conclusion: The management of adult patients receiving anticoagulation therapy with LMWH is complex and it is reflected in their demographic and clinical characteristics. It is important to determine Anti-Xa activity to monitor the use of enoxaparin as anticoagulant therapy because of the high variability found in certain groups of patients.
Keywords : anticoagulation; low molecular weight heparin; coronary syndrome; Anti-Xa activity.